Telix Appoints Paul Schaffer as Chief Technology Officer
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) has appointed Dr. Paul Schaffer as its new Chief Technology Officer (CTO), effective April 07, 2025. Dr. Schaffer joins from ARTMS Inc., where he served as CTO for seven years, and TRIUMF, Canada's particle accelerator research centre, where he was Director of Life Science since 2012.
In his new Vancouver-based role, Dr. Schaffer will oversee Telix's technological advancement in radiopharmaceutical research, development, and clinical applications. His responsibilities will encompass chemistry, physics, artificial intelligence, dosimetry, and data analytics, working alongside Chief Scientist Dr. Michael Wheatcroft's team.
Dr. Schaffer is notably recognized for developing the ARTMS QUANTM Irradiation System® (QIS®) for large-scale isotope production, which was later acquired by Telix in 2024, and for transforming TRIUMF's Life Sciences program, including the design of a multi-cyclotron radiochemistry facility.
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) ha nominato il Dr. Paul Schaffer come nuovo Chief Technology Officer (CTO), con effetto dal 7 aprile 2025. Il Dr. Schaffer proviene da ARTMS Inc., dove ha ricoperto il ruolo di CTO per sette anni, e da TRIUMF, il centro di ricerca canadese per acceleratori di particelle, dove è stato Direttore delle Scienze della Vita dal 2012.
Nel suo nuovo ruolo a Vancouver, il Dr. Schaffer supervisionerà i progressi tecnologici di Telix nella ricerca sui radiofarmaci, nello sviluppo e nelle applicazioni cliniche. Le sue responsabilità comprenderanno chimica, fisica, intelligenza artificiale, dosimetria e analisi dei dati, collaborando con il team del Chief Scientist Dr. Michael Wheatcroft.
Il Dr. Schaffer è particolarmente riconosciuto per lo sviluppo del sistema di irradiazione ARTMS QUANTM® (QIS®) per la produzione di isotopi su larga scala, successivamente acquisito da Telix nel 2024, e per la trasformazione del programma di Scienze della Vita di TRIUMF, inclusa la progettazione di una struttura di radiochimica multi-ciclotrone.
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) ha nombrado al Dr. Paul Schaffer como su nuevo Chief Technology Officer (CTO), con efecto a partir del 7 de abril de 2025. El Dr. Schaffer se une a Telix proveniente de ARTMS Inc., donde se desempeñó como CTO durante siete años, y de TRIUMF, el centro de investigación canadiense de aceleradores de partículas, donde fue Director de Ciencias de la Vida desde 2012.
En su nuevo puesto en Vancouver, el Dr. Schaffer supervisará el avance tecnológico de Telix en la investigación de radiofármacos, desarrollo y aplicaciones clínicas. Sus responsabilidades incluirán química, física, inteligencia artificial, dosimetría y análisis de datos, trabajando junto al equipo del Chief Scientist Dr. Michael Wheatcroft.
El Dr. Schaffer es reconocido por desarrollar el sistema de irradiación ARTMS QUANTM® (QIS®) para la producción de isótopos a gran escala, que fue adquirido por Telix en 2024, y por transformar el programa de Ciencias de la Vida de TRIUMF, incluida la planificación de una instalación de radioquímica de múltiples ciclotrones.
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX)는 2025년 4월 7일부로 Dr. Paul Schaffer를 새로운 Chief Technology Officer (CTO)로 임명했습니다. Dr. Schaffer는 7년 동안 CTO로 재직했던 ARTMS Inc.와 2012년부터 생명과학 책임자로 있었던 캐나다의 입자 가속기 연구 센터 TRIUMF에서 합류합니다.
밴쿠버에 위치한 새로운 역할에서 Dr. Schaffer는 방사성 의약품 연구, 개발 및 임상 응용에서 Telix의 기술 발전을 감독할 것입니다. 그의 책임에는 화학, 물리학, 인공지능, 선량계 및 데이터 분석이 포함되며, Chief Scientist Dr. Michael Wheatcroft의 팀과 협력할 것입니다.
Dr. Schaffer는 대규모 동위원소 생산을 위한 ARTMS QUANTM 방사선 조사 시스템® (QIS®)을 개발한 것으로 유명하며, 이는 2024년에 Telix에 인수되었고, TRIUMF의 생명과학 프로그램을 혁신하고 다중 사이클로트론 방사화학 시설을 설계한 것으로 알려져 있습니다.
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) a nommé le Dr Paul Schaffer comme nouveau Chief Technology Officer (CTO), avec effet à partir du 7 avril 2025. Le Dr Schaffer rejoint Telix en provenance d'ARTMS Inc., où il a été CTO pendant sept ans, et de TRIUMF, le centre de recherche canadien sur les accélérateurs de particules, où il était directeur des sciences de la vie depuis 2012.
Dans son nouveau rôle basé à Vancouver, le Dr Schaffer supervisera l'avancement technologique de Telix dans la recherche sur les radio-pharmaceutiques, le développement et les applications cliniques. Ses responsabilités comprendront la chimie, la physique, l'intelligence artificielle, la dosimétrie et l'analyse des données, en collaboration avec l'équipe du Chief Scientist Dr. Michael Wheatcroft.
Le Dr Schaffer est particulièrement reconnu pour le développement du système d'irradiation ARTMS QUANTM® (QIS®) pour la production d'isotopes à grande échelle, qui a été acquis par Telix en 2024, et pour la transformation du programme de sciences de la vie de TRIUMF, y compris la conception d'une installation de radiochimie multi-cyclotron.
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) hat Dr. Paul Schaffer als neuen Chief Technology Officer (CTO) ernannt, der am 7. April 2025 sein Amt antreten wird. Dr. Schaffer kommt von ARTMS Inc., wo er sieben Jahre lang CTO war, sowie von TRIUMF, dem kanadischen Forschungszentrum für Teilchenbeschleuniger, wo er seit 2012 Direktor für Lebenswissenschaften war.
In seiner neuen Rolle in Vancouver wird Dr. Schaffer die technologische Weiterentwicklung von Telix im Bereich Radiopharmaforschung, Entwicklung und klinische Anwendungen überwachen. Zu seinen Aufgaben gehören Chemie, Physik, künstliche Intelligenz, Dosimetrie und Datenanalyse, während er mit dem Team des Chief Scientist Dr. Michael Wheatcroft zusammenarbeitet.
Dr. Schaffer ist besonders bekannt für die Entwicklung des ARTMS QUANTM Irradiationssystems® (QIS®) zur großtechnischen Isotopenproduktion, das 2024 von Telix übernommen wurde, und für die Umgestaltung des Lebenswissenschaftsprogramms von TRIUMF, einschließlich der Planung einer Multi-Cyclotron-Radio-Chemie-Anlage.
- Strategic appointment of experienced CTO with proven track record in radiopharmaceutical innovation
- Integration of ARTMS acquisition's key leadership strengthens technological capabilities
- Expansion of R&D leadership team with expertise in AI, dosimetry, and data analytics
- None.
MELBOURNE, Australia and INDIANAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.
Dr. Schaffer has been CTO at ARTMS Inc. (ARTMS) (acquired by Telix in 2024) for the past seven years, as well as Director, Life Science at TRIUMF, Canada’s particle accelerator research centre, since 2012. Based in Vancouver, Canada, Dr. Schaffer is widely recognized for his role in the buildout and transformation of the TRIUMF Life Sciences program, which included design and construction of a major multi-cyclotron radiochemistry facility and the development of the ARTMS QUANTM Irradiation System® (QIS®) for large-scale isotope production, which was commercialized and later acquired by Telix.
As Telix CTO, Dr. Schaffer will be responsible for harnessing the power of technology to advance Telix’s capabilities in radiopharmaceutical research, development, and clinical applications. Dr. Schaffer will cover areas including chemistry, physics, artificial intelligence (AI), dosimetry, and data analytics, complementing the work of Telix’s Chief Scientist, Dr. Michael Wheatcroft, and his team in driving cutting-edge research and development (R&D).
Dr. Schaffer said, “I’m excited to be taking on this role at such a pivotal time for Telix, as the Company advances rapidly toward its mission of transforming patient care. Telix has a bold commitment to innovation, and I’m thrilled to collaborate with this talented team to help drive R&D for the technologies behind the next generation of radiotherapeutics.”
Dr. Christian Behrenbruch, Telix Managing Director and Group Chief Executive Office, said, “Paul has an impressive track record of driving innovation in life sciences technology, including his groundbreaking work in large-scale isotope production. I have first-hand experience of Paul’s impressive intellect, ideas and passion through his work at TRIUMF and with ARTMS, so it is a great pleasure to have him join the broader Telix team as we continue to lead radiopharmaceutical innovation.”
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com
Legal Notices
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.
FAQ
What role has Dr. Paul Schaffer been appointed to at Telix (TLX) in April 2025?
What are Dr. Schaffer's main responsibilities as Telix's (TLX) new CTO?
What significant achievements did Dr. Schaffer bring to Telix (TLX) from his previous roles?
How does the 2024 ARTMS acquisition connect to Telix's (TLX) new CTO appointment?
